PhaseV, a leader in software and machine learning (ML) for clinical trial optimization, has appointed Hamza Sheikh as its new Head of Business Development. This strategic appointment comes at a crucial time as the company experiences growing global interest in its technology, which leverages causal ML to extract actionable insights from clinical data and design advanced adaptive clinical trials, ultimately improving both efficiency and success rates.
Leadership Perspective
Raviv Pryluk, PhD, CEO and Co-founder of PhaseV, expressed his enthusiasm about Sheikh’s appointment: “As we expand globally, we are partnering with CROs, biotech, and pharma companies of all sizes to address drug development challenges by providing tools that help identify subgroups and endpoints more likely to succeed in future clinical trials. We are proud to welcome Hamza to the team. His leadership experience and proven track record will be instrumental in expanding our customer base, forging new partnerships, and furthering our continued growth.”
Hamza Sheikh’s Background
Hamza Sheikh will spearhead PhaseV’s global business development and partnership initiatives, bringing over a decade of experience in leading biotech operations, transactions, and strategy. Before joining PhaseV, he was with PathAI, an AI technology company focused on precision pathology solutions, where he successfully led R&D partnerships with major pharmaceutical and biotech firms.
Previous Experience
- Nimbus Therapeutics: As Director of Business Development, Sheikh led due diligence efforts for the significant $6 billion acquisition of Nimbus Lakshmi by Takeda.
- UroGen Pharma: He also served as Director of Business Development, Strategy, and Commercial Development, further enhancing his expertise in the biotech sector.
“PhaseV has quickly emerged as an important player in causal machine learning and clinical trial optimization, with growing interest around its AdaptV platform,” said Sheikh. “I am excited to join the company at this crucial stage and look forward to working with the team to further advance clinical trial optimization and contribute to improved patient outcomes.”
